GT Medical Technologies, announced that it has raised $37 million in Series D financing round. The financing round was led ...

Digital health firms in the city raised $4 billion in 2024, up 60% from the previous year, according to a report released ...

BofA Securities, Goldman Sachs & Co. LLC, Evercore ISI, Guggenheim Securities and Cantor acted as joint bookrunners for the offering.

Oil futures ended lower Friday, contributing to a loss for the week, though prices held on to a gain for the month as traders awaited a tariff decision by President Donald Trump on crude imports from ...

Recent health news covers significant events like Pfizer's diversity program settlement, AstraZeneca's halted UK investment, ...

This summary highlights significant health news, covering topics such as HIV treatment during U.S. aid pauses, Pfizer's diversity program legal settlement, AstraZeneca's halted UK investment, data ...

Obesity-drug maker Metsera Inc.’s stock jumped 47% on Friday as the biggest gainer among three initial public offerings ...

Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion.

Metsera, a clinical-stage biotechnology firm, debuted on the Nasdaq Global Select Market today. After initially offering its ...

An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...

Metsera, along with Maze Therapeutics, gave U.S. health care first-time share sales its best month since October.